Observational studyCardiovascular diabetology2025
Interplay of glycated hemoglobin and traditional risk factors for the risk of atherosclerotic cardiovascular disease and all-cause mortality in people without diabetes.
Observational study in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Determinants of HbA1c Variability Across Clinical Subgroups: When the Same Value Does Not Reflect the Same Biological Risk.Medicina (Kaunas, Lithuania) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the impact of glycated hemoglobin A1c (HbA1c) in individuals without diabetes and at the extremes of cardiovascular risk factor (CVRF) burden on the incidence of atherosclerotic cardiovascular disease (ASCVD) and all-cause mortality.
methodsWe studied 20,360 U.S. adults, initially free of diabetes and ASCVD from the CARDIA, MESA, ARIC, and FOS cohorts, all with available HbA1c data. The mean (standard deviation) age was 57.1 (9.1) years [56.2% women and 21.9% Black]. Using multivariable Cox proportional hazard regression, ASCVD and all-cause mortality were analyzed over a median 16.7-year follow-up across categories of CVRF burden (0, 1, 2, or 3 of dyslipidemia, smoking, and hypertension) and HbA1c levels (< 5.0%, 5.0-5.4% [reference], 5.5-5.9%, and 6.0-6.4%).
resultsDuring follow-up, 3592 ASCVD events (17.6%) and 6627 deaths (32.6%) occurred. The hazard ratios (HRs) and 95% confidence intervals (CIs) for HbA1c levels of 5.5-5.9% and 6.0-6.4% for ASCVD were 1.17 (1.09-1.26) and 1.59 (1.42-1.78), respectively. The corresponding HRs for mortality were 1.14 (1.07-1.20) and 1.35 (1.24-1.47). HbA1c < 5.0% was also associated with an elevated mortality risk (HR, 95% CI 1.17, 1.07-1.28). Among individuals with 0 CVRFs, the HRs for ASCVD risks ranged from 1.26 (1.02-1.55) for HbA1c 5.5-5.9% to 1.68 (1.12-2.54) for HbA1c 6.0-6.4%. For those with 3 CVRFs, the corresponding HRs were 1.22 (0.88-1.69) and 2.00 (1.35-2.97). Similar findings were observed for all-cause mortality. Subgroup analysis revealed that HbA1c ≥ 5.5% was associated with an increased mortality risk in non-Black individuals but did not reach statistical significance in Black individuals (P interaction < 0.001).
conclusionsHbA1c testing in individuals without diabetes may help identify those at higher risk for ASCVD and mortality, even at the extremes of CVRF burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.